Takizawa, Hotake
Hara, Yuko
Mizobe, Yoshitaka
Ohno, Taisuke
Suzuki, Sadafumi
Inoue, Ken
Takeshita, Eri
Shimizu-Motohashi, Yuko
Ishiyama, Akihiko
Hoshino, Mikio
Komaki, Hirofumi
Takeda, Shin’ichi
Aoki, Yoshitsugu http://orcid.org/0000-0002-9038-7506
Funding for this research was provided by:
Grants-in-Aid for Research on Nervous and Mental Disorders
Japan Agency for Medical Research and Development (18ek0109239h0002, 18lm0203066h0001, 18lm0203069h0001)
MEXT | Japan Society for the Promotion of Science (18K07544)
Grants-in-Aid for Research on Nervous and Mental Disorders
Article History
Received: 15 November 2018
Accepted: 12 February 2019
First Online: 7 March 2019
Change Date: 7 February 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: The National Center of Neurology and Psychiatry is now developing NS-065/NCNP-01, an exon 53 skipping drug for DMD with the Nippon Shinyaku Co., Ltd.